Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool
This article was originally published in PharmAsia News
BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership
You may also be interested in...
China’s second-largest CRO opens new Shanghai facility to support its largest client.
Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma
BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai
BEIJING - The leadership of Chinese contract research organization ShangPharma this week outlined plans to continue expanding the outfit's drug and biopharmaceutical research services through next year to attract more of the top international players